Efforts to elicit broadly neutralizing antibodies (bNAbs) against HIV-1 require understanding germline bNAb recognition of HIV-1 envelope glycoprotein (Env). The VRC01-class bNAb family derived from the VH1-2*02 germline allele arose in multiple HIV-1–infected donors, yet targets the CD4-binding site on Env with common interactions. Modified forms of the 426c Env that activate germline-reverted B cell receptors are candidate immunogens for eliciting VRC01-class bNAbs. We present structures of germline-reverted VRC01-class bNAbs alone and complexed with 426c-based gp120 immunogens. Germline bNAb–426c gp120 complexes showed preservation of VRC01-class signature residues and gp120 contacts, but detectably different binding modes compared to mature bNAb-gp120 complexes. Unlike typical antibody-antigen interactions, VRC01–class germline antibodies exhibited preformed antigen-binding conformations for recognizing immunogens. Affinity maturation introduced substitutions increasing induced-fit recognition and electropositivity, potentially to accommodate negatively-charged complex-type N-glycans on gp120. These results provide general principles relevant to the unusual evolution of VRC01–class bNAbs and guidelines for structure-based immunogen design.https://doi.org/10.7554/eLife.13783.001
When human immunodeficiency virus-1 (HIV-1) infects humans it can cause a serious disease that damages the immune system. Currently there is no cure for this disease and there are no vaccines available to halt the spread of the virus. Researchers are hoping to be able to develop a single vaccine that can protect individuals against every form (or strain) of HIV-1, but this has proved difficult because many different versions of the virus exist.
An effective vaccine triggers long-lasting immunity to a particular virus or microbe by activating the production of proteins called antibodies that identify and help to destroy the threat. Research has shown that most individuals infected with HIV-1 produce antibodies that can only recognize a few HIV strains. However, there are rare individuals who produce “broadly neutralizing antibodies”; that is, antibodies that can recognize and help to kill 90% or more of HIV-1 strains. Understanding how broadly neutralizing antibodies are produced in infected individuals may aid the development of a vaccine that can protect others from the many circulating strains of HIV.
When an individual encounters a virus, immature antibodies are modified to generate mature antibodies that bind more effectively to specific virus proteins. Here, Scharf et al. investigated how a class of broadly neutralizing antibodies called VRC01-class antibodies, which bind to an HIV protein called gp120, are produced. The experiments used a technique called X-ray crystallography to reveal the three-dimensional structures of immature versions of these antibodies when they are bound to gp120.
Scharf et al. discovered that, unlike most antibodies, the overall final structure of VRC01 antibodies is formed before the antibody matures. Instead of making large changes to the structure of these antibodies, the maturation process makes VRC01-class antibodies become more positively charged, which allows them to bind to gp120 proteins on a wider variety of HIV viruses. These findings suggest that it may be possible to use modified gp120 proteins in vaccines to trigger the production of broadly neutralizing antibodies against HIV.https://doi.org/10.7554/eLife.13783.002
The HIV-1 envelope (Env) spike, a trimer of gp120-gp41 heterodimers, is the only target of neutralizing antibodies (Abs). Rapid mutation combined with structural features of the Env trimer that hide conserved features of the HIV-1 spike result in induction of mainly strain-specific neutralizing Abs in most infected individuals. However, broadly neutralizing Abs (bNAbs) evolve in a minority of HIV-1–infected individuals after several years of infection. These Abs are of considerable interest for HIV-1 therapeutic efforts because they can prevent and treat infection in animal models (reviewed in ([West et al., 2014]) and exhibited efficacy against HIV-1 in a human clinical trial (Caskey et al., 2015). Thus, it is believed that an immunogen that could elicit bNAbs would induce a protective immune response against infection by HIV-1.
Highly potent bNAbs against the conserved CD4-binding site (CD4bs) on gp120 that were derived from the VH1-2*02 variable heavy chain (HC) gene have been isolated from at least nine HIV-1–infected individuals (Scheid et al., 2011; Wu et al., 2010; Zhou et al., 2013; 2015; Wu et al., 2011; Georgiev et al., 2013). These bNAbs exhibit unusually high levels of somatic hypermutation, with changes in both complementarity determining regions (CDRs) and framework regions (FWRs) (Klein et al., 2013). As exemplified by VRC01, the first such bNAb to be isolated (Wu et al., 2010), VRC01-class bNAbs share a common mode of gp120 binding in which the VH1-2*02-derived variable heavy (VH) domain mimics CD4 (Wu et al., 2010; Zhou et al., 2010; 2013; 2015; Diskin et al., 2011). Signature features of the HCs of VRC01-class bNAbs that explain their derivation from the VH1-02*02 gene segment include Trp50HC, Asn58HC, and Arg71HC; an additional signature residue, Trp100BHC within CDRH3, is derived from the joining of the D and J gene segments to the VH gene segment during V(D)J recombination (Diskin et al., 2012). The variable light (VL) domains of VRC01-class bNAbs, which can be derived from several different VL germline gene segments, require a short (five residues) CDRL3 loop to allow interactions with gp120 V5 and loop D (Diskin et al., 2012) and often include a deletion in CDRL1 to avoid clashes with an N-linked glycan attached to Asn276gp120 (Zhou et al., 2010; 2013; Scharf et al., 2013). The LC contact residues of VRC01-like bNAbs and the short CDRL3 are not germline encoded (Diskin et al., 2012). Because VRC01-class bNAbs are highly potent, have demonstrated efficacy in animal and human trials, and evolved in multiple HIV-1–infected donors who were infected with different strains of HIV-1, they are considered a promising target for elicitation by vaccination with designed immunogens.
The first step in eliciting an Ab is binding to its precursor germline-encoded B cell receptor by an antigen or immunogen with adequate affinity to initiate B cell activation and affinity maturation (Batista and Neuberger, 1998). Although the unmutated VH1-2*02 gene segment includes the signature VH domain residues for interacting with the CD4bs, germline-reverted versions of VRC01-class bNAbs do not bind to Env trimers or to gp120 (Scheid et al., 2011; Zhou et al., 2010; Diskin et al., 2012; Scharf et al., 2013; Hoot et al., 2013; Ota et al., 2012; McGuire et al., 2013). In previous studies, we investigated VRC01-class germline recognition of Env by solving a crystal structure of the clade A/E 93TH057 gp120 core bound to a half germline, half mature chimeric VRC01-class Ab (NIH45-46CHIM) in which the inferred germline HC was paired with the mature LC to permit binding to an unmodified gp120 (Scharf et al., 2013). Two forms of designed gp120-based immunogens were subsequently engineered to bind and activate germline HC/LC VRC01-class B cell receptors: gp120 outer domain-only constructs (eOD-GT6 and eOD-GT8) (Jardine et al., 2013; 2015) and gp120s modified from the clade C 426c Env (McGuire et al., 2013; 2014; 2016). Crystal structures of the inferred germline Fab of VRC01 complexed with eOD-GT6 and NIH45-46CHIM complexed with gp120 revealed a similar angle of approach for binding as mature Fabs and conservation of the signature VRC01-class interactions with gp120 residues (Scharf et al., 2013; Jardine et al., 2013). However, questions concerning germline B-cell receptor recognition of gp120 remained because neither structure represented a complex between a fully germline VRC01-class Ab and a complete gp120 core. Here, we present crystal structures of inferred germline VRC01-like Abs alone and complexed with 426c-based gp120 immunogen cores and compare and contrast their gp120 recognition with structures of mature VRC01-class Ab/gp120 complexes. The analyses shed insight on the evolution pathway by which Abs derived from VH1-2*02 germline mature towards broad recognition of the CD4bs on gp120 and provide structural information that will facilitate design of immunogens to elicit VRC01-class bNAbs.
The antigen-binding Fabs of two VRC01-class Abs isolated from different patients, NIH45-46 and 3BNC60 (Scheid et al., 2011), were generated in their inferred germline forms (NIH45-46GL and 3BNC60GL) using sequences described in previous studies (Scharf et al., 2013; Hoot et al., 2013; McGuire et al., 2013; Dosenovic et al., 2015). Compared with mature NIH45-46 (NIH45-46MAT), NIH45-46GL contained 40 HC and 23 LC substitutions in addition to a two-residue insertion in CDRL1. 3BNC60GL contained 38 HC and 25 LC substitutions in addition to a four-residue deletion in HC framework region 3 (FWR3HC) and a four-residue insertion in CDRL1 compared with 3BNC60MAT (Figure 1). Two versions of germline-binding gp120s were expressed as gp120 cores with N/C termini and V1-V2 and V3 loop truncations (Zhou et al., 2010): (i) 426c.NLGS.TM1△V1-3 (hereafter referred to as 426c.TM1△V1-3), a modified version of the clade C 426c Env in which the V1, V2 and V3 loops were truncated and three potential N-linked glycosylation sites at gp120 residues Asn276gp120, Asn460gp120 and Asn463gp120 were removed by mutation (N276D, N460D, and N463D) (McGuire et al., 2013; 2014), and (ii) 426c.TM4△V1-3, a modification of 426c.TM1△V1-3 with additional substitutions (D276N, S278R, G471S) (McGuire et al., 2016; Dosenovic et al., 2015). 426c.TM1△V1-3 binds to germline VRC01 and NIH45-46 (McGuire et al., 2013; 2014), and 426c.TM4△V1-3 binds to germline versions of 12A21, 3BNC60, VRC-CH31, VRC-PG19 and VRC-PG20 in addition to germline VRC01 and NIH45-46 (McGuire et al., 2016).
We used a surface plasmon resonance (SPR)-based assay to compare the binding of NIH45-46GL, 3BNC60GL, NIH45-46MAT, and 3BNC60MAT to gp120 cores including the 426c immunogens and a representative gp120 (93TH057) used for structural studies with mature bNAbs (Figure 2). As expected, the germline-reverted Abs did not bind detectably to 93TH057 gp120, but NIH45-46GL bound to both 426c.TM1ΔV1-3 and 426c.TM4ΔV1-3 gp120s with equilibrium dissociation constants (KDs) of ~0.7 and 3 μM, respectively. As previously described (McGuire et al., 2013; 2014), 3BNC60GL did not bind to 426c.TM1ΔV1-3, but showed detectable binding to 426c.TM4ΔV1-3 gp120. By contrast, NIH45-46MAT and 3BNC60MAT bound to all gp120s with nM or higher affinity (Figure 2).
Crystal structures of NIH45-46GL bound to 426c.TM1△V1-3 and 3BNC60GL bound to 426c.TM4△V1-3 were solved to 3.4 Å and 3.1 Å resolution, respectively (Table 1). We also solved structures of unbound 3BNC60GL and 426c.TM4△V1-3 (at 1.9 Å and 2.0 Å resolution, respectively), and a complex structure of a 426c.TM4△V1-3 bound to 3BNC55MAT, a mature VRC01-class Ab (Table 1). We compared the new structures to previously-reported complex structures of NIH45-46CHIM/93TH057 gp120 and VRC01GL/eOD-GT6 (PDB codes 4JDT and 4JPK), unbound structures of NIH45-46GL and VRC01GL (PDB codes 4JDV and 4JPI) (Scharf et al., 2013; Jardine et al., 2013), and representative mature VRC01-class Fab/gp120 complexes; e.g., NIH45-46MAT/93TH057 gp120 and 3BNC117MAT/93TH057 gp120 (PDB codes 3U7Y and 4JPV) (Zhou et al., 2013; Diskin et al., 2011).
To evaluate the structural plasticity of the inferred germline versions of the VRC01-class bNAbs, we superimposed available structures of inferred germline Fabs in their free and antigen-complexed forms. Superimpositions of bound and unbound forms of NIH45-46GL and 3BNC60GL Fabs (this study) and bound and unbound VRC01GL (Jardine et al., 2013) revealed no major structural changes (Figure 3A,C,E). We previously noted slight differences between bound and unbound NIH45-46MAT in the conformations of CDRs L1 and H3 and positions of the Tyr89CDRL3 and Tyr74FWRH3 side chains (Figure 3G) (Diskin et al., 2011), but the counterpart residues in NIH45-46GL were not affected by gp120 binding (Figure 3F). In addition, superimpositions of bound and unbound 3BNC60GL Fab showed no major structural changes except in CDRL1, which either flipped the backbone conformation of the Asp28LC-Asn31LC segment (in the case of one Fab/gp120 complex in the crystallographic asymmetric unit; Figure 3H) or was partially disordered (in the case of the second Fab/gp120 complex in the asymmetric unit), thus avoiding clashes with loop D of gp120 despite a four-residue insertion in CDRL1. In the mature Ab 3BNC60MAT (and presumably its close relative 3BNC117MAT), a disrupted β-strand in the region of Pro61HC was reordered upon binding to gp120 (Klein et al., 2013), but no notable differences in the bound and free forms of 3BNC60GL were seen in the counterpart region, which contained Ala61HC instead of Pro61HC (Figure 3H,I). Root mean square deviations (rmsds) for superimposing all Cα atoms in the VHVL domains of bound and unbound Fabs of NIH45-46GL, 3BNC60GL, and VRC01GL were low (0.54 Å–0.73 Å) (Figure 3K). Thus the association of the VH and VL domains and the conformations of the CDR loops and surrounding FWRs found in the unbound forms were largely maintained in the germline-inferred Abs upon binding to their antigens.
Superpositions of bound and unbound forms of the mature counterparts of these bNAbs (using a closely-related unbound Fab structure when necessary) also revealed relatively small rmsd values with the exception of the 1.66 Å rmsd when comparing free 3BNC60MAT and complexed 3BNC117MAT due to the disrupted β-sheet structure near Pro61HC of free 3BNC60MAT (Figure 3I) (Klein et al., 2013) – when the disrupted β-strand was excluded, the rmsd dropped to 0.72 Å (Figure 3K). Thus the mature bNAbs (NIH45-46MAT, 3BNC60MAT, and VRC01MAT) are overall largely preformed to recognize antigen, but exhibited more antigen binding-induced conformational flexibility within individual CDR loops and/or the FWRs than the germline-inferred Abs.
We addressed potential changes in antigen structure resulting from germline and mature Ab binding by comparing structures of free and bound 426c.TM4△1–3 gp120 core. The 426c.TM4△1–3 structure was solved using crystals of the gp120 core alone and again as part of the analysis of the 3BNC60GL/426c.TM4△V1-3 crystals in which the crystallographic asymmetric unit included two copies of unbound 426c.TM4△V1-3 gp120 along with two copies of the 3BNC60GL/426c.TM4△V1-3 complex. We compared the unbound 426c.TM4△V1-3 structures to those of 426c.TM4△V1-3 complexed with Fabs from 3BNC60GL and from a mature VRC01-class Ab, 3BNC55MAT. We found no major structural rearrangements resulting from binding of either a germline or mature Ab (Figure 3J,K), suggesting that the 426c gp120 core immunogens are preformed for binding to germline and mature forms of VRC01-class Abs. Since these immunogens lack the V1V2 and V3 loops, potential rearrangement of these regions in the context of the trimer upon binding remains to be studied.
The new germline Fab/gp120 structures, NIH45-46GL/426c.TM1△V1-3 and 3BNC60GL/426c.TM4△V1-3, showed interface interactions in which the germline Fab contacts with the CD4-binding loop and loops D and V5 of the gp120 outer domain were similar to those observed for mature VRC01-class Fab/gp120 complexes (Zhou et al., 2010; 2015; Diskin et al., 2011). This confirms the assumption of similar recognition modes derived from germline Fab-antigen complex structures that either did not contain a full gp120 core (VRC01GL/eOD-GT6) (Jardine et al., 2013) or included a mature Ab LC (NIH45-46CHIM/93TH057) (Scharf et al., 2013). In particular, both NIH45-46GL and 3BNC60GL interacted with the CD4-binding loop on gp120 using conserved interactions that mimic CD4 binding, first described for the complex of VRC01MAT with 93TH057 gp120 (Zhou et al., 2010), in which VRC01-class bNAbs mimic CD4 using backbone atoms in the VH domain C” strand to engage with the CD4-binding loop on gp120 (Wu et al., 2010; Zhou et al., 2010; 2015; Diskin et al., 2011). As found in NIH45-46MAT and 3BNC117MAT complexes with 93TH057 gp120s, Gly54HC in NIH45-46GL and 3BNC60GL makes a main chain hydrogen bond with Asp368gp120 (Figure 4A,B). The 3BNC60GL complex with 426c.TM4△V1-3 gp120 includes an additional main chain hydrogen bond between Gly57HC and Gly365gp120 that is not made in the 3BNC117MAT/gp120 complex. Similarly, NIH45-46GL Thr58HC makes an additional side chain hydrogen bond with Gly365gp120. NIH45-46MAT further engages the CD4 binding loop of gp120 using water-mediated hydrogen bonds between Val57HC and Gly366gp120/Asp368gp120 (Diskin et al., 2011). While the resolution of the germline Fab complex structures did not permit placement of water molecules, residues in the C′′ strand of both NIH45-46GL and 3BNC60GL are positioned to engage in water-mediated hydrogen bonds with additional CD4-binding loop residues in gp120. Thus, our analyses showed that NIH45-46GL and 3BNC60GL, like their mature counterparts, use the C” strand in VH to mimic Leu44CD4 and Lys46CD4 interactions with the gp120 CD4 binding loop.
We next examined the interactions of the VRC01-class signature residues (Diskin et al., 2012). As found for mature VRC01-like Fab/gp120 complexes (e.g., PDB codes 3U7Y and 4JPV) and the half-germline NIH45-46CHIM/93TH057 gp120 complex (Scharf et al., 2013), the VH1-2*02 germline-encoded heavy chain signature residues (Trp50HC, Asn58HC, Arg71HC) engaged in the predicted interactions with 426c.TM1△V1-3 and 426c.TM4△V1-3 in their complexes with NIH45-46GL and 3BNC60GL: i.e., Trp50HC and Asn58HC made hydrogen bonds with Asn280gp120 and Arg456gp120, respectively, and Arg71HC formed a salt bridge with Asp368gp120 to mimic the Arg59CD4–Asp368gp120 interaction (Kwong et al., 1998) (Figure 4C,D). The final signature interaction within the heavy chain, CDRH3 residue Trp100BHC, also made the predicted hydrogen bonding interaction with Asn279gp120. In summary, NIH45-46GL and 3BNC60GL make all predicted HC VRC01-class signature contacts with the CD4-binding loop, the V5 loop, and loop D to bind to gp120.
Potent VRC01-class bNAbs pair with LCs that acquire signature residues, Trp67LC and Glu96LC, during somatic hypermutation and/or V-J joining, and are associated with short loops for two of the CDRs: CDRL1 (resulting from a two- to four-residue deletion relative to the germline LC) and a five-residue CDRL3 (Diskin et al., 2012). Comparison of the NIH45-46GL/426c.TM1△V1-3 and 3BNC60GL/426c.TM4△V1-3 structures with their mature counterparts (NIH45-46MAT/93TH057 and 3BNC117MAT/93TH057; PDB codes 3U7Y and 4JPV) revealed no major structural differences between the LC contacts with gp120 cores (Figure 4E,F). The greater number of residues in the CDRL1s in the germline Fab-containing complexes (two and four additional residues in NIH45-46GL and 3BNC60GL, respectively) result in wider, rather than longer, loops than their mature counterparts (Figure 5A). The wider CDRL1s in the germline Fabs are not extended towards gp120, thereby preventing clashes with the 426c.TM1△V1-3 and 426c.TM4△V1-3 gp120s (Figure 5A). However, CDRL1 is near the position of the Asn276gp120N-linked glycan (removed by mutagenesis in gp120-based immunogen candidates including the 426c.TM1△V1-3 and 426c.TM4△V1-3 gp120s and the eOD-GT gp120 outer domains) (McGuire et al., 2013; 2014; 2016; Jardine et al., 2013; 2015). To address whether this glycan would clash with the larger CDRL1 loops of germline VRC01-class Abs, we superimposed the NIH45-46GL/426c.TM1△V1-3 and 3BNC60GL/426c.TM4△V1-3 complex structures with the structure of a mature Ab/gp120 complex that includes a partially ordered Asn276gp120 glycan (the structure of 45-46m2 complexed with 93TH057 gp120 core; PDB code 4JKP) (Diskin et al., 2013). The superimposed germline Fabs showed no clashes between CDRL1 and ordered Asn276gp120 glycan residues (Figure 5B–D). However, given the flexibility of N-linked glycans, some conformations of the Asn276gp120-linked glycan could interfere with binding germline CD4bs Abs. VRC01-class Abs VRC-CH31 and 12A21 do not have deletions in CDRL1, but accommodate the Asn276gp120-linked glycan due to a pair of glycines that increase the conformational flexibility of CDRL1 (Zhou et al., 2013). The CDRL1 of 3BNC60GL is of the same length as the VRC-CH31 and 12A21 CDRL1s and lacks glycines, yet has the conformational flexibility to avoid clashes with loop Dgp120 and the Asn276gp120 glycan (Figure 5E). Therefore, CDRL1 deletions or enhanced loop flexibility due to somatically substituted glycine residues is not required for binding to gp120 although these adaptations likely lead to improved affinity in mature bNAbs adapted to bind to HIV-1 Envs that are not optimized to accommodate germline Ab binding.
We previously noted that the buried surface area on both the Ab and the gp120 was larger in mature Fab/gp120 complexes than in the NIH45-46CHIM/93TH057 gp120 complex (Scharf et al., 2013). Here, we extended this analysis to include comparisons with the HC/LC germline Fab complexes with 426c.TM1△V1-3 and 426c.TM4△V1-3 (Figure 6A,B, Supplementary file 1). The surface area buried on gp120 by both germline Fabs was only slightly smaller than that buried by the corresponding mature Abs (1,039 Å2 vs. 1,190 Å2 for NIH45-46GL vs. NIH45-46MAT and 939 Å2 vs. 1,033 Å2 for 3BNC60GL vs. 3BNC117MAT), with gains in buried surface area in loop D, inner domain and bridging sheet residues of gp120 (Figure 6C). The surface area buried on the Fab HCs by gp120 was smaller than that buried by the corresponding mature Abs with no change in the area buried on the LCs (784 Å2 vs. 1,130 Å2 for NIH45-46GL HC vs. NIH45-46MAT HC and 731 Å2 vs. 802 Å2 for 3BNC60GL vs. 3BNC117MAT). The difference was most pronounced for the NIH45-46GL/NIH45-46MAT comparison, in which the mature Fab gained contacts in CDRH3.
Mature VRC01-class Abs show similar angles of approach for binding to gp120 ([Zhou et al., undefined] and references therein). However, comparison of the orientations of the germline Fab interactions with gp120 in the NIH45-46GL/426c.TM1△V1-3 and 3BNC60GL/426c.TM4△V1-3 structures revealed differences compared with their mature Fab counterparts (Figure 7A). To systematically analyze these differences, we calculated the rotation and translation for the VH domains of mature, chimeric, and germline Fabs bound to gp120s when compared with a reference Fab/gp120 structure, the VRC01MAT/93TH057 complex (Zhou et al., 2010) (PDB code 3NGB) (Figure 7B). We found that the mature Fab/gp120 complex structures clustered in the recognition mode for VRC01-class Ab recognition of gp120 (Zhou et al., undefined). The germline Fab complexes with the 426c gp120 immunogens exhibited larger rotations and translations relative to the VRC01 reference structure, with the VRC01GL/eOD-GT6 complex showing an intermediate orientation. To verify that the orientations observed for the germline Fabs bound to the 426c gp120s are relevant for binding to Env trimer, we aligned the 3BNC60GL/426c.TM4△V1-3 structure onto the gp120 region of a native-like Env trimer structure (BG505 SOSIP.664; PDB code 5CEZ) (Garces et al., 2015), comparing this orientation with the alignment of a VRC01MAT/gp120 complex (PDB code 3NGB) (Zhou et al., 2010) onto the same Env trimer structure (Figure 7C). This alignment suggests that the different orientation of the 3BNC60GL VH domain with respect to gp120 moves it away from the adjacent gp120 subunit, suggesting this orientation would be sterically compatible when binding to Env trimer.
The orientation differences for the NIH45-46GL/426c.TM1△V1-3 and 3BNC60GL/426c.TM4△V1-3 structures could result from structural characteristics of germline Fabs, immunogen characteristics allowing for germline Fab recognition, or a combination of these factors. Arguing in favor of the idea that the 426c immunogens could select for an altered binding mode, we note that a mature Ab (3BNC55MAT) complex with 426c.TM4△V1-3 exhibited rotation and translation values closer to those of the germline Fab/426c immunogen complexes than those of mature Ab-gp120 complexes. In addition, the VRC01GL complex with another germline-binding immunogen, eOD-GT6, exhibited a binding mode that differed from the VRC01 reference complex more than most of the mature Fab/gp120 complexes. We also note that the half germline NIH45-46CHIM Fab clustered with the mature Fab/gp120 complexes when bound to the 93TH057 gp120 (Figure 7B). This is consistent with the idea that designed immunogens capable of binding germline VRC01-class bNAbs select for a slightly different antibody-binding mode than that adopted by mature VRC01-class Fabs bound to gp120s not capable of supporting germline antibody binding.
To address potential global changes in VRC01-class bNAbs during maturation from germline to mature forms, we calculated electrostatic potentials of the binding surfaces of germline and mature Fabs. Comparisons of electrostatic surface potentials revealed a striking shift to more positively-charged antigen combining sites due to maturation (Figure 8). The more negatively-charged (3BNC60GL) or neutral (NIH45-46GL, VRC01GL) properties of the antigen-binding sites of the germline Fabs may interfere with interactions with complex-type N-glycans on gp120 containing negatively-charged sialic acids; in particular, the Asn276gp120 carbohydrate, typically a complex-type N-glycan (Binley et al., 2010; Go et al., 2011), would likely make unfavorable interactions with the neutral or negatively charged surfaces of 3BNC60GL, NIH45-46GL, or VRC01GL Fabs. Such interactions were prevented in the 426c gp120- and eOD-based immunogens by mutation of the Asn276gp120N-linked glycosylation sequon (McGuire et al., 2013; 2014; Jardine et al., 2013; 2015). Similarly, potentially unfavorable electrostatic interactions between the germline Fabs and the Asn463gp120N-linked glycan, also usually a complex-type N-glycan (Binley et al., 2010; Go et al., 2011), were prevented by mutation of the Asn463gp120 glycosylation sequon in the 426c gp120- and eOD-based immunogens (McGuire et al., 2013; 2014; 2016; Jardine et al., 2013; 2015).
The process by which B cells produce high-affinity Abs starts with antigen binding to an unmutated, germline B cell receptor produced by random joining of V, D, and J or V and J gene segments. Affinity maturation is the process by which Abs with higher antigen-binding affinity are created through somatic hypermutation of the germline B cell receptor (Victora and Nussenzweig, 2012). Many anti-HIV-1 bNAbs, including VRC01-class CD4bs bNAbs, are heavily somatically mutated, likely through successive rounds of hypermutation and selection of B cells in response to rapid mutation of HIV-1 Env (West et al., 2014; Klein et al., 2013). Mature VRC01-class bNAbs achieve nucleotide somatic mutation frequencies of 32% and 20% in HC and LC variable region genes, respectively, whereas the mutation frequencies of more typical affinity-matured human Abs rarely exceeds 10% (Kwong and Mascola, 2012). Although heavily somatically mutated, VRC01-class bNAbs are promising targets for vaccine design because they have evolved in multiple donors from a common human germline VH gene segment, VH1-2*02, to recognize HIV-1 Env using conserved interactions (Scheid et al., 2011; Wu et al., 2010; Zhou et al., undefined; Zhou et al., 2013; Diskin et al., 2011; Zhou et al., 2010).
The first step in targeted attempts to raise VRC01-class bNAbs by immunization requires identification of an immunogen that binds to the germline configuration of the B-cell receptor, but germline-reverted versions of VRC01-like bNAbs generally do not bind HIV-1 Env (Scheid et al., 2011; Zhou et al., 2010; Diskin et al., 2012; Scharf et al., 2013; Hoot et al., 2013; Ota et al., 2012; McGuire et al., 2013; Jardine et al., 2013). Although antigens designed to bind to predicted unmutated germline precursors of VRC01-class bNAbs have been constructed and evaluated (McGuire et al., 2013; 2014; 2016; Jardine et al., 2013; 2015; Dosenovic et al., 2015), structural comparisons of germline and mature versions of VRC01-class bNAbs bound to gp120-based immunogens were not available. Here, we report the results of structural studies of immunogens that bind to the inferred germline precursors of VRC01-class bNAbs, discovering both general principles and details of interactions that can guide structure-based immunogen design.
A surprising finding revealed by our structural comparisons of germline and mature VRC01-class Fabs was an increase in electropositive surface potential in the antigen-combining site for the mature Fab compared with the germline-inferred Fab, which we observed in the three VRC01-class Abs (NIH45-46, 3BNC60, and VRC01) for which germline and mature Fab structures were available for calculating electrostatic potentials. This marked shift to a more electropositive antigen combining site may also occur in other VRC01-class bNAbs, particularly those whose LCs are derived from the LC germline KV1-33 gene segment. Mature VRC01-class bNAbs appear on average to have a higher net nominal charge of their VHVL domains (+4.9) than the average human Ab (+3.1; as calculated from sequenced human B-cell repertoires) (Table 2) (Rubelt et al., 2012), and the VH1-2*02 gene segment yields a sequence with a nominal net charge of +5, higher than the average human VH gene segment (+2 to +3). However, the KV1-33 LC germline gene segment, used by some VRC01-class Abs, yields a protein sequence with a nominal net charge of -4, in contrast to the KV3-20 gene segment (utilized by other VRC01-class Abs) with a net charge of zero. Perhaps to compensate for these negative charges, after maturation of the KV1-33–derived VRC01-class bNAbs 3BNC117, VRC-CH31, and 12A12, the portions of the VL domain encoded by the KV1-33 gene segment have net nominal charge changes of +5, +3, and +6, respectively.
The trend towards increased electropositivity with Ab maturation does not apply to all HIV-1 Env-specific Abs: maturation of CH58, a non-neutralizing Ab against the gp120 V2 loop that was raised by vaccination in the RV144 trial (Liao et al., 2013), did not involve a shift to increased electropositive character (Figure 8—figure supplement 1), consistent with its epitope being centered on a positive residue, Lys169gp120, within the gp120 V2 loop (Nicely et al., 2015). However, the developmental pathway of potent V1V2-directed bNAbs involves increased positivity of the CDRH3 loop, which starts as highly electronegative in part due to sulfated tyrosines, but accumulates positive charges during maturation that partially compensate for the negatively-charged sulfates (Doria-Rose et al., 2014). A trend towards electropositive combining sites in mature HIV-1 bNAbs could rationalize their tendencies towards polyreactivity (binding more than one antigen), which has been observed at higher frequencies for broadly neutralizing, as compared with non-neutralizing, Abs against HIV-1 (Liu et al., 2015). For example, increased non-specific binding to cardiolipin and nucleic acids, negatively-charged antigens commonly used in polyreactivity assays, correlates with polyreactive properties of Abs (Mouquet et al., 2010).
We suggest that evolution of increased electropositivity during maturation of VRC01-class bNAbs (and perhaps other HIV-1 bNAbs; Figure 8—figure supplement 1) facilitates interactions with heavily glycosylated HIV-1 Env spikes that include complex N-linked glycans containing negatively charged sialic acids. Indeed, somatic hypermutation to increase electropositivity of an Ab combining site may be a strategy utilized by Abs against other viruses containing heavily glycosylated Env proteins, such as influenza and Ebola. In the case of VRC01-class bNAbs, this strategy may be part of a multi-pronged approach of the humoral immune response against the CD4 binding site of HIV-1 for accommodating and/or for avoiding the N-linked Env glycan attached to Asn276gp120, a site that can include complex-type N-glycans (Behrens et al., 2016), with other strategies including deletions to shorten CDRL1 and increasing CDRL1 flexibility by somatic mutations to glycine (Zhou et al., 2013). In addition to these steric considerations for potentially unfavorable interactions between CDRL1 and the Asn276gp120-linked glycan, the neutral or negatively charged character of the germline Fab combining sites provides a structural justification for the necessity to eliminate the Asn276gp120- and Asn463gp120-linked N-glycans from eOD- and gp120-based immunogen candidates to achieve binding to inferred germline B-cell receptors (McGuire et al., 2013; Jardine et al., 2013; 2015; McGuire et al., 2014; 2016). The structures presented here, taken together with immunogen requirements for achieving germline Ab binding and previous structural analyses of mature VRC01-class Abs (Zhou et al., undefined; Zhou et al., 2010; 2013; McGuire et al., 2013; 2014; 2016; Jardine et al., 2013; 2015), suggest that the initiating antigen(s) in a natural pathway to induce VRC01-class Abs in HIV-1–infected individuals involve viral variants that lack the Asn276gp120 (5% of HIV-1 strains in the Los Alamos Database) and the Asn463gp120N-glycans (~80% of HIV-1 strains in the Los Alamos Database) (http://www.hiv.lanl.gov/content/index). Alternatively, a natural VRC01-class eliciting antigen could be the result of glycan heterogeneity within a single HIV-1 strain that produced variants containing high mannose, rather than complex-type, N-glycans at Asn276gp120 and/or Asn463gp120, consistent with observations of glycan heterogeneity at individual N-linked glycosylation sites within single HIV-1 strains (Go et al., 2011; Behrens et al., 2016).
Although antibody-antigen recognition modes represent a continuum of binding mechanisms, germline precursors to affinity-matured Abs have been suggested to display structural flexibility to allow expanded antigen recognition through induced fit mechanisms, whereas affinity maturation through somatic hypermutation was assumed to convert recognition to a lock-and-key model (Foote and Milstein, 1994; Wedemayer et al., 1997; Thorpe and Brooks, 2007). Induced fit modes of Ab-antigen recognition involve changes in the conformations of backbone and sidechain atoms of both the Ab and the antigen (Blackler et al., 2011; Li et al., 2007; Rosen et al., 2005; Sinha and Smith-Gill, 2005; Verdaguer et al., 1996), with large changes in the Ab usually occurring in the CDR loops. By contrast, lock-and-key recognition involves a minimum of conformational changes between the bound and unbound states of the antigen and Ab. Here, we showed that for the VRC01 class of CD4bs bNAbs, the maturation pathway for antigen binding from germline Ab to affinity-matured Ab does not involve changes from induced fit to lock-and-key binding mechanisms. Instead, the 426c gp120 immunogens bind NIH45-46GL and 3BNC60GL without requiring notable conformational changes in either the Ab or the antigen; thus both are largely preformed for binding. The largely lock-and-key binding mechanism for germline VRC01-class recognition of antigen may be rationalized by the fact that germline VRC01-class CD4bs Abs face major steric constraints when binding to HIV-1 Env trimer due to the recessed location of the epitope and its shielding by glycans from the target and adjacent gp160 monomers (West et al., 2014; Zhou et al., 2015). VRC01-like CD4bs bNAbs bind Env at an acute angle using mostly CDRs and FWRs of VH in part because these steric constraints likely do not allow a Fab to bind perpendicular to the CD4bs on a closed Env trimer without clashes with the adjacent trimer subunit. These constraints may also not permit bNAbs or their germline precursors to undergo the major conformational changes characteristic of induced-fit binding and instead select for rare Ab sequences that are preformed to recognize their epitope in this highly sterically-constrained setting. The lock-and-key binding mechanism of VRC01-class recognition also may reflect that the binding interaction is dominated (relative to other Abs) by VH domain FWRs, and that these would be unlikely to undergo large induced-fit conformational changes.
Structural analyses of germline and mature versions of the non-neutralizing HIV-1 Ab CH58 showed a more typical path for Ab-antigen recognition; the germline precursor used a combination of induced fit and lock-and-key binding modes to recognize a V2 peptide antigen: its CDRL2 loop was preformed for binding but CDRL3 changed conformation upon antigen binding (Nicely et al., 2015). The conformation of CDRL3 became fixed in mature CH58 through limited somatic mutation compared with VRC01-class Abs (11 total substitutions in CH58 VHVL) (Nicely et al., 2015). Thus, the conversion from induced fit to lock-and-key binding may be applicable for HIV-1 Abs such as CH58 that include the relatively small numbers of somatic mutations typical for most Abs, but not for VRC01-class Abs, whose maturation process involves a much higher number (>60) of mutations.
The finding of what can be described as lock-and-key recognition for germline Fabs binding to the 426c gp120 immunogens contrasts with recognition of unmodified gp120s used for structural studies of complexes with mature VRC01-class bNAbs that do not bind or bind only poorly to germline Abs. For example, when bound to the unmodified 93TH057 gp120, the CDRH3 of the germline HC in the NIH45-46CHIM-93TH057 complex structure was partially disordered, presumably to avoid clashes with a gp120 not optimized for binding to germline Abs (Scharf et al., 2013). An example of structural rearrangements in a mature VRC01-class bNAb bound to an unmodified gp120 is illustrated by a study of the Ala61HCPro substitution in the C” β-strand of the β-sheet framework in the VH domains of the 3BNC60/3BNC117 HIV-1 bNAbs. This substitution is required for maximal neutralization potency of the mature bNAbs, yet it disrupts the C” β-strand of the VH domain in the unbound Fab and decreases its thermal stability (Klein et al., 2013), with the β-sheet framework being restored through a large conformational change when the mature Fab binds gp120 (Zhou et al., 2013; Klein et al., 2013). Taken together, the findings of what appears to be lock-and-key style germline Fab recognition with increased flexibility upon maturation for the highly somatically-mutated VRC01-class bNAbs contradict the assumption of induced fit for germline Ab recognition and lock-and-key fit for mature Ab binding (Foote and Milstein, 1994; Wedemayer et al., 1997; Thorpe and Brooks, 2007). This assumption was also challenged by studies of the maturation of other HIV-1 Abs: for example, CH103, a non-VRC01-class CD4-binding site bNAb, exhibits changes in the relative orientation of its VH and VL domains during maturation (Fera et al., 2014), and the HIV-1 gp41-directed bNAb 4E10 exhibits increased flexibility in its combining site during maturation (Finton et al., 2014). Thus, the rare events that result in evolution of HIV-1 bNAbs can fall outside of typical Ab maturation pathways.
We speculate that 426c-based immunogens are able to bind germline precursors of VRC01-class bNAbs as a complete gp120 core because they can engage the unbound conformation of these Abs. This may allow the gp120-based immunogens to overcome a loss of binding affinity due to slow on-rates in the context of the already weak binding affinities of immature B cell receptors. The improved binding of the 426c-based gp120 immunogens to some germline VRC01-class Abs upon removal of the V1V2 and V3 loops from the 426c.TM1△V1-3 and 426c.TM4△V1-3 gp120s could result from the removal of steric occlusion by the variable loops (also not present in the eOD immunogens (Jardine et al., 2013; 2015), and which may be flexible in the context of a gp120 or eOD), removal of glycans attached to these loops, or a combination of these factors. Thus, our results suggest implementation of a general strategy in which a germline-binding antigen is designed to be electrostatically compatible with the neutral or negatively charged antigen-binding surfaces of germline VRC01 Fabs and to fit in lock-and-key mode to the combining site of a germline Fab, with consideration paid to the slightly different angles of approach reported here for germline Fab binding to the gp120-based immunogens. The general principles established here for germline VRC01-class recognition of gp120 can be used to guide efforts to design and produce immunogens capable of eliciting broad and potent CD4bs Abs of the VRC01 class in uninfected people, facilitating the development of an efficacious vaccine to protect from HIV-1 infection.
NIH45-46GL and 3BNC60GL were constructed as described previously by using the VH1-2*02 germline V gene segment, the appropriate germline VL gene segment, and mature sequences for CDRH3 and CDRL3 (Scharf et al., 2013; Hoot et al., 2013; McGuire et al., 2013; Dosenovic et al., 2015). The Abs were expressed and purified as described (Scharf et al., 2013). Briefly, IgGs and 6xHis-tagged Fab fragments were produced by transient cotransfection of appropriate HC and LC plasmids into HEK293-6E cells followed by purification of the secreted proteins from cell supernatant using protein A (GE Healthcare; Pittsburg, PA) or Ni-NTA (GE Healthcare) affinity chromatography and Superdex 200 16/60 (GE Healthcare) size exclusion chromatography (SEC). gp120 proteins were expressed as cores with N/C termini and V1-V2 and V3 loop truncations as described for previous structural studies (Zhou et al., 2010) by transient transfection of suspension-adapted HEK293-S cells. gp120s were purified using Ni-NTA affinity chromatography and Superdex 200 16/60 SEC. Proteins were stored in 20 mM Tris, pH 8.0, and 150 mM sodium chloride (TBS buffer) supplemented with 0.02% (wt/vol) NaN3.
Crystals of 3BNC60GL Fab were obtained by combining 0.2 μL of a 15 mg/mL protein solution with 0.2 μL of 0.1 M bicine pH 9.1 and 10% (w/v) PEG 1,500 at 20°C and cryoprotected in mother liquor supplemented with 20% (v/v) glycerol. Crystals of 426c.TM4△V1-3 gp120 were obtained by combining 0.2 μL of a 10 mg/mL protein solution with 0.2 μL of 0.1 M sodium citrate tribasic dihydrate pH 5.0, 10% (w/v) PEG 6000 and 0.2 M sodium thiocyanate at 20°C and cryoprotected in mother liquor supplemented with 30% (v/v) 2-propanol. Complexes of 3BNC60GL/426c.TM4△V1-3, NIH45-46GL/426c.TM1△V1-3 and 3BNC55MAT/426c.TM4△V1-3 were produced by incubating Fabs and gp120s at a 3:1 molar ratio at 4°C for 16 hrs, followed by Endoglycosidase H (New England BioLabs; Ipswich, MA) treatment and SEC purification. Fractions containing complexes were combined and concentrated as indicated below. Crystals of 3BNC60GL/426c.TM4△V1-3 complex were obtained by combining 0.2 μL of a 20 mg/mL protein solution with 0.2 μL of 0.1 M imidazole pH 7.0, 8% (w/v) PEG10000, 10 mM calcium chloride dihydrate at 20°C and cryoprotected in mother liquor supplemented with 20% (w/v) ethylene glycol. Crystals of NIH45-46GL/426c.TM1△V1-3 complex were obtained by combining 0.2 μL of a 20 mg/mL protein solution with 0.2 μL of 0.1 M sodium citrate pH 5.5, 22% (w/v) PEG 1000, 3% (w/v) xylitol at 20°C and cryoprotected in mother liquor supplemented with 20% (w/v) ethylene glycol. Crystals of 3BNC55MAT/426c.TM4△V1-3 complex were obtained by combining 0.2 μL of a 15 mg/mL protein solution with 0.2 μL of 0.1 M sodium citrate pH 5.5, 18% (w/v) PEG 1,000, 3% (w/v) ethylene glycol at 20°C and cryoprotected in mother liquor supplemented with 20% (w/v) ethylene glycol. All crystals were flash cooled in liquid nitrogen.
X-ray diffraction data were collected at the Stanford Synchrotron Radiation Lightsource beamline 12–2 outfitted with a Pilatus 6M pixel detector (Dectris; Baden-Dättwil, Switzerland). XDS was used to index, integrate and scale the data (Kabsch, 2010). The structures were refined using an iterative approach of refinement with Phenix (Adams et al., 2010) and manual model building in Coot (Emsley and Cowtan, 2004). Crystals of 3BNC60GL Fab (one molecule per asymmetric unit) diffracted to 1.9 Å, and the structure was solved by molecular replacement using 3BNC117MAT Fab (PDB code 4JPV) VHVL with CDR loops removed and CH1CL as search models. The final model (Rwork = 19.6%, Rfree = 21.0%) has 99%, 1%, and 0% of residues in the favored, allowed and disallowed regions, respectively, of the Ramachandran plot. Crystals of NIH45-46GL/426c.TM1△V1-3 complex (one Fab-gp120 complex per asymmetric unit) diffracted to 3.4 Å, and the structure was solved by molecular replacement using 93TH057 gp120 core (PDB code 4JDT) and NIH45-46GL Fab VHVL with CDR loops removed and CH1CL (from PDB code 4JDV) as the search models. The final model (Rwork = 27.9%, Rfree = 28.6%) has 95.7%, 4.3% and 0% of residues in the favored, allowed, and disallowed regions, respectively, of the Ramachandran plot. Some parts of the CH1CL domain were not well ordered in the electron density, probably because this domain did not make crystal packing contacts. To account for regions of disorder, unresolved CH1CL residues were assigned occupancies of 0. Crystals of 426c.TM4△V1-3 gp120 diffracted to 2.0 Å, contained two molecules in the asymmetric unit and the structure was solved by molecular replacement using 426c.TM1△V1-3 as the search model. The final model (Rwork = 20.7%, Rfree = 23.2%) has 97.7%, 2.3% and 0% of residues in the favored, allowed, and disallowed regions, respectively, of the Ramachandran plot. Crystals of 3BNC60GL/426c.TM4△V1-3 complex diffracted to 3.1 Å, contained two Fab-gp120 complexes and two unbound gp120 molcules in the asymmetric unit and the structure was solved by molecular replacement using 426c.TM4△V1-3 gp120 core and 3BNC60GL Fab VHVL and CH1CL with CDR loops removed as the search models. The final model (Rwork = 20.3%, Rfree = 26.7%) has 97%, 2.9% and 0.1% of residues in the favored, allowed and disallowed regions, respectively, of the Ramachandran plot. Crystals of 3BNC55MAT/ 426c.TM4△V1-3 complex diffracted to 3.0 Å, contained two Fab-gp120 complexes in the asymmetric unit and the structure was solved by molecular replacement using 426c.TM4△V1-3 gp120 core and 3BNC117MAT Fab (from PDB code 4JPV) VHVL and CH1CL with CDR loops removed as the search models. The final model (Rwork = 24.0%, Rfree = 27.9%) has 98%, 1.7%, and 0.3% of residues in the favored, allowed, and disallowed regions, respectively, of the Ramachandran plot.
Buried surface areas were calculated using PDBePISA (Krissinel and Henrick, 2007) and a 1.4 Å probe. Hydrogen bonds were assigned tentatively due to the low resolution of the complex structures using the following criteria: a distance of <3.5 Å, and an A-D-H angle of >90°. Structures were superimposed and molecular representations were generated with PyMOL (Schrödinger LLC, 2011) and UCSF Chimera (Pettersen et al., 2004). Rmsd calculations following pairwise Cα alignments were done in PyMOL without outlier rejection.
All SPR measurements were performed on a Biacore T200 (GE Healthcare) at 20°C using HBS-EP+ (GE Healthcare) as the running buffer. A CM5 chip (GE Healthcare) containing 3000 resonance units (RUs) of primary amine-coupled protein A (Pierce; Waltham, MA) was used to capture HIV-1 IgGs (3BNC60GL, NIH45-46GL, VRC01GL, 3BNC60MAT, NIH45-46MAT) and a non-gp120-binding control IgG (mG053) by injecting 0.25 μg/mL or 0.1 μg/mL solutions of germline or mature IgG, respectively. Remaining protein A binding sites were blocked by injecting 1 μM Fc. gp120 cores (426c.TM1△V1-3, 426c.TM4△V1-3, 93TH057) were injected over the flow cells at increasing concentrations (top concentration of 16 μM for germline Abs, 200 nM for mature Abs) at a flow rate of 50 μL/min for 240 s and allowed to dissociate for 500 sec. Regeneration of flow cells was achieved by injecting one pulse each of 10 mM glycine pH 2 and 1 M guanidine-HCl at a flow rate of 90 μL/min. Kinetic analyses were used after subtraction of reference curves to derive on/off rates (ka/kd) and binding constants (KDs) with a 1:1 binding model with or without bulk refractive index change (RI) correction as appropriate (Biacore T200 Evaluation software).
The VRC01MAT/93TH057 gp120 complex (PDB code 3NGB) was used as the reference structure for comparisons of angles of approach of Fab recognition of gp120s (Figure 7B). The center of mass of the VRC01 VH domain was placed at the origin and its principal axes of inertia were aligned with the Cartesian axes using AMORE from the CCP4 program suite (CCP4, 1994). The 3NGB complex was then aligned with the centered VH domain. For comparisons with other complexes, each Fab/gp120 complex was aligned with the 3NGB gp120 chain using LSQMAN (Kleywegt, 1996). The transformation matrix between the aligned Fab/gp120 VH domain and the VRC01 VH domain was then calculated by LSQMAN.
PHENIX: a comprehensive Python-based system for macromolecular structure solutionActa Crystallographica. Section D, Biological Crystallography 66:213–221.https://doi.org/10.1107/S0907444909052925
Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope GlycoproteinCell Reports, 10.1016/j.celrep.2016.02.058.
The CCP4 suite: programs for protein crystallographyActa Crystallographica 50 (Pt 5):760–763.
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117Nature, 522, 10.1038/nature14411.
Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodiesThe Journal of Experimental Medicine 210:1235–1249.https://doi.org/10.1084/jem.20130221
Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domainsProceedings of the National Academy of Sciences of the United States of America 111:10275–10280.https://doi.org/10.1073/pnas.1409954111
Conformational isomerism and the diversity of antibodiesProceedings of the National Academy of Sciences of the United States of America 91:10370–10374.https://doi.org/10.1073/pnas.91.22.10370
Use of non-crystallographic symmetry in protein structure refinementActa Crystallographica. Section D, Biological Crystallography 52:842–857.https://doi.org/10.1107/S0907444995016477
Inference of macromolecular assemblies from crystalline stateJournal of Molecular Biology 372:774–797.https://doi.org/10.1016/j.jmb.2007.05.022
The structure of a polyQ-anti-polyQ complex reveals binding according to a linear lattice modelNature Structural & Molecular Biology 14:381–387.https://doi.org/10.1038/nsmb1234
Polyreactivity and autoreactivity among HIV-1 antibodiesJournal of Virology 89:784–798.https://doi.org/10.1128/JVI.02378-14
Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodiesThe Journal of Experimental Medicine 210:655–663.https://doi.org/10.1084/jem.20122824
Anti-HIV B Cell lines as candidate vaccine biosensorsJournal of Immunology 189:4816–4824.https://doi.org/10.4049/jimmunol.1202165
UCSF Chimera--a visualization system for exploratory research and analysisJournal of Computational Chemistry 25:1605–1612.https://doi.org/10.1002/jcc.20084
Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibodyProceedings of the National Academy of Sciences of the United States of America 110:6049–6054.https://doi.org/10.1073/pnas.1303682110
The PyMOL Molecular Graphics System, version
1.2r3preThe PyMOL Molecular Graphics System.
Molecular evolution of affinity and flexibility in the immune systemProceedings of the National Academy of Sciences of the United States of America 104:8821–8826.https://doi.org/10.1073/pnas.0610064104
Germinal centersAnnual Review of Immunology 30:429–457.https://doi.org/10.1146/annurev-immunol-020711-075032
Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120Proceedings of the National Academy of Sciences of the United States of America 109:E2083.https://doi.org/10.1073/pnas.1208984109
Arup K ChakrabortyReviewing Editor; Massachusetts Institute of Technology, United States
In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.
Thank you for submitting your work entitled "Structural basis for germline antibody recognition of gp120-based HIV-1 immunogens" for consideration by eLife. Your article has been favorably evaluated by three reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation was overseen by Tadatsugu Taniguchi as Senior editor.
The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. Please find below the general and specific comments.
The induction of bnAbs against HIV by vaccination will undoubtedly require the activation of their germline precursors. The design of such immunogens is a major problem. In this work, the interactions made between germline VRC01-class Abs and gp120 constructs were studied. Five new crystal structures were solved: one unliganded germline VRC01-class Ab, one unliganded gp120 that has been modified for germline Ab binding, two complex structures of GL VRC01-class Abs bound to the engineered gp120 core and one complex structure of a VRC01-class bnAb bound to the engineered gp120 core. An in depth comparison between these five structures as well as previously solved structures is carried out to evaluate conformational changes in the GL Abs and bnAbs, gp120/Ab contacts, buried surface area, angles of approach, glycan interactions, and electrostatics.
While, as noted by the authors, much of the analysis of angle of approach, BSA, conserved contacts and preformed conformation of the Abs can already be found in West/Bjorkman (PNAS, 2012), Diskin/Bjorkman (J Exp Med, 2013), Jardine/Schief (Science, 2013) and Scharf/Diskin (PNAS, 2013), since structures of a complex between a fully germline VRCO1-class Ab and a complex gp120 core were not available, the addition of the five crystal structures, especially the 426c bound structures, is valuable to the field. Moreover, many of the findings derived from the structures are significant. However, the following points need to be addressed in a revised manuscript.
1) Comparison of "binding mode" as reported by translation distance and rotation angle: this discussion is interesting but incomplete and requires further clarification.
The wire diagrams in Figure 7A imply that the portions of the antibodies proximal to gp120 are much better aligned than the distal portions. This begs the question: Might the distance/angle differences in Figure 7B be due to protein flexibility in the Fab domains accommodating differences in crystal packing? This point should be carefully examined and discussed to support the relevance of the measurements to vaccine design or therapeutic antibody design.
The true target of these antibodies is a native trimer that may restrict the translation distance and angle of approach more severely than the core-gp120s in the crystal structures analyzed here. Because these antibodies are broadly neutralizing, we already know that they can bind native trimers of diverse strains. Are the authors confident that the variations in distance and angle reported here would be reproduced if crystal structures were solved with the same antibodies in complex with native-like trimers? A key uncertainty in this regard is caused by the bridging sheet, an important aspect of the VRC01-class interaction with gp120 that has been shown to be in very different conformations in core-gp120 structures (complexed with CD4 or VRC01-class bnAbs) as compared to native-like trimer structures (Lyumkis et al. Science 2013, Figure 5A). Further uncertainty comes from the V2 loop that is known to restrict access to the CD4 binding site on the trimer, yet is absent from the structures analyzed here. Finally, the many glycans around the CD4 binding site on the trimer may restrict the translation distance and measured angle. The authors should attempt to use the published structures of the BG505 SOSIP native-like trimer and other native-like trimers to assess the relevance of their distance/angle measurements on core-gp120 to the interaction of VRC01-class bnAbs with native-like trimers.
The authors have computed translation distance and rotation angle only for a subset of the VRC01-class bnAbs for which high resolution structures are available. This incomplete analysis means that the distance/angle distribution for VRC01-class bnAbs interacting with core-gp120 might be broader (or narrower) than currently represented in Figure 7B. The incomplete analysis leaves open the possibility that the distance/angle values for the TM1 and TM4 structures may not be as divergent from the previously known structures as implied by Figure 7B. The authors should include analysis of several (if not all) currently available structures of VRC01-class bnAbs in complex with core-gp120.
The authors should comment on the fact that the eOD is a more minimal antigen than 426c yet it appears to better preserve the distance/angle of the VRC01-class interaction (Figure 7B). Can the authors discern the structural reason why 426c supports a more unusual distance/angle interaction mode even though it contains the inner domain and bridging sheet that are absent from eOD? This type of analysis could help guide further immunogen design.
The authors have computed translation distance and rotation angle for one antibody (3BNC117MAT) crystallized with three different gp120 molecules, but they should provide some discussion of the variation if any in the distance/angle values among these three structures. This would provide a useful reference for the effects of gp120 strain variation and crystal packing on the distance/angle values that are being measured.
2) The discussion of how the electrostatics of the VRC01-class Abs' interaction is changed by affinity maturation is very interesting. The reason offered by the authors is that this helps binding to the glycans. But, the arguments pertinent to this issue in the Discussion – are a bit confusing. At the start of the fifth paragraph it is stated that interactions with glycans are facilitated by the change in electrostatic potential. Later in that paragraph it is stated that this helps avoiding interactions with the glycan. Some rewording may be appropriate. Perhaps, the authors mean to say that somatic hypermutation on the LC has two objectives-the main one being to avoid clashes with the N276 glycan that will block binding, and secondly to make additional contacts to the glycan?
Even though this finding is of interest, the discussion of this being related to interactions with complex glycans with negatively charged sialic acids needs to be tempered. The degree to which the N276 glycan or other glycans near the VRC01-class epitope are complex type rather than high mannose is not well understood. The existing data on glycosylation profiles of HIV Env are incomplete as they were largely measured on gp120 molecules rather than native-like trimers.
3) The discussion of lock-and-key versus induced-fit binding mechanisms is simplistic because in reality there is likely a continuum of binding mechanisms rather than only two ways to bind. Could this discussion be nuanced?
4) The authors paint a picture that VRC01-class development involves "lock-and-key" germline Fab interaction with increasing flexibility during maturation. However, perhaps the Discussion should be modified to account for the following:
It is interesting that the 426c gp120 interaction with germline Fabs appears to involve little conformational change in the Fab. However, the authors seem to be making a leap when they attempt to contrast this finding with their previous observation that the CDRH3 of NIH45-46CHIM was disordered in the interaction with an "unmodified" gp120 is (Discussion, eighth paragraph). Could that difference not also be due to different crystal packing? Alternatively, could this be due to interaction with a different strain of gp120? Or due to the fact that one antibody is "germline" while the other is a chimera of "germline"-H with mature-L? It seems difficult to draw a strong conclusion from the contrast given. This is compounded by the fact that the CDRH3 makes little contact in most of the VRC01-class/core-gp120 crystal structures, hence whether the CDRH3 is ordered or not may not be highly important to the interaction.
To support the idea that VRC01-class maturation involves increasing flexibility, the authors then give the example (Discussion, eighth paragraph) of the Ala61HCPro mutation in the 3BNC60/3BNC117 members of this class. However, the generality of this example is unclear. Do other members of the class exhibit similar features?https://doi.org/10.7554/eLife.13783.027
- Michel C Nussenzweig
- Pamela J Bjorkman
- Pamela J Bjorkman
- Louise Scharf
- Stuart A Sievers
- Michel C Nussenzweig
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Bill and Melinda Gates Foundation, ACS or CHRP.
We thank the Caltech Protein Expression Center for producing antibody and gp120 proteins, generation of suspension-adapted HEK293-S cells and use of the Biacore T200. Operations at the Stanford Synchrotron Radiation Lightsource are supported by the US Department of Energy and the National Institutes of Health. MCN is a Howard Hughes Medical Institute investigator. This research was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health Grant HIVRAD P01 AI100148 (PJB and MCN); (the content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health), Collaboration for AIDS Vaccine Discovery grants from The Bill and Melinda Gates Foundation (grant IDs 1040753 to PJB and 1124068 to MCN), the American Cancer Society (Grant PF-13-076-01-MPC to LS), and the California HIV/AIDS Research Program (CHRP grant F12-CT-214 to SAS).
- Arup K Chakraborty, Reviewing Editor, Massachusetts Institute of Technology, United States
- Received: December 14, 2015
- Accepted: March 5, 2016
- Version of Record published: March 21, 2016 (version 1)
© 2016, Scharf et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.